(Hypertension. 1999;33:312-317.)
© 1999 American Heart Association, Inc.
Scientific Contributions |
Effects of Human Prorenin in Rats Transgenic for Human Angiotensinogen
From the Franz Volhard Clinic at the Max Delbrück Center for Molecular Medicine, Medical Faculty of the Charité, Humboldt University of Berlin (D.N.M., R.U., F.C.L.) and the University of Erlangen-Nürnberg (K.F.H.), Germany; and Hoffmann-La Roche (S.M., V.B.) and Actelion (W.F.), Basel, Switzerland.
Correspondence to Friedrich C. Luft, MD, Franz Volhard Clinic, Wiltberg Strasse 50, 13122 Berlin, Germany. E-mail luft{at}fvk-berlin.de
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Abstract—The physiological role of prorenin is unknown; however, the possibility that prorenin inhibits renin locally has been suggested. We tested the hypothesis that prorenin may be an endogenous competitor for renin uptake in the tissue. We also investigated whether prorenin can be activated to active renin and affect mean arterial pressure (MAP). Isolated perfused hindquarters of rats transgenic for human angiotensinogen were infused with human renin and/or prorenin. The plateau phase of angiotensin (Ang) I release 15 minutes after cessation of infusions was used as a parameter for renin uptake. Renin (10 ng/mL for 15 minutes) caused sustained release of Ang I (153±16 fmol/mL). Coinfusion with a 15-fold excess of prorenin did not affect local Ang I formation (153±19 fmol/mL). Prorenin infusion alone showed no activation to active renin. In addition, we investigated MAP and plasma Ang II levels after injection of saline (
MAP, -1±2 mm Hg; 40±5 fmol/mL
Ang II), 9 ng renin (MAP, +37±3 mm Hg; 378±39 fmol/mL), and
144 ng prorenin (MAP, +10±5 mm Hg; 61±5 fmol/mL) and the
coinjection of renin and prorenin (MAP, +41±4 mm Hg; 305±23
fmol/mL) in anesthetized rats. The data show that prorenin was
not activated to active renin and did not affect MAP in
short-term experiments. Renin-induced Ang formation was not affected by
prorenin. Renin may have been taken up specifically because of its
physical and chemical properties or because of nonspecific
sequestration in the extravascular space. We conclude that prorenin
does not act as an endogenous antagonist for
the long-lasting effects of renin in the vascular wall. Moreover,
prorenin does not affect acute renin-related effects on blood
pressure.
Key Words: rats, transgenic • angiotensinogen • angiotensin • prorenin • renin • hindlimbs
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Circulating renin, a key regulatory enzyme of the renin-angiotensin system (RAS), plays a major role in cardiovascular homeostasis, including the regulation of blood pressure, salt balance, and tissue remodeling. Angiotensin (Ang) formation has been reported to occur both in the circulation and at tissue sites. In fact, the tissues are the major site of Ang I and Ang II formation, and the release of locally formed Ang II contributes to the circulating levels of these peptides.1 2 3 Kidney-derived renin is the major source of tissue renin.4 Renin can be taken up by several tissues to react locally with its substrate angiotensinogen (Aogen).5 6 Several renin-binding proteins have been described; nevertheless, the mechanism of renin uptake is still unclear.7 8 9 10 Sealey et al9 described a prorenin/renin-binding receptor. By competing for binding to this receptor or to other receptors, prorenin may be a natural antagonist of tissue-directed RAS.
Prorenin is the biosynthetic precursor of renin. In humans, as much as 90% of circulating renin exists in its enzymatically inactive form.11 However, prorenin is both the primary and final product of renin gene expression in most tissues.12 13 14 Juxtaglomerular cells of rat and human kidneys constitute the main site of prorenin synthesis and the exclusive site of its intracellular processing to active renin. After bilateral nephrectomy, plasma prorenin levels fall >50% within several hours and remain at this level indefinitely, indicating that other tissues are also involved in prorenin synthesis.15 16 In vitro, prorenin can be activated to active renin by cryoactivation, acid activation, or proteolytic activation.11 15 17 18 19 20 21 Recently, van Kesteren et al10 reported that prorenin is taken up in neonatal rat cardiac myocytes and fibroblasts by the mannose-6 phosphate receptor followed by intracellular activation. However, the role of prorenin in physiology and pathology is still unknown.
The goal of our study was to evaluate the local and systemic effects of human renin and/or human prorenin. We investigated the uptake and local activation of prorenin in the vascular wall of the isolated perfused hindlimb model. We also tested the hypothesis that prorenin may act as an endogenous competitor for renin-related effects in the tissue. We then investigated whether prorenin can be activated in vivo and affect mean arterial pressure (MAP). To avoid confounding effects of endogenous renin produced by the rat, we used rats harboring the human Aogen gene as a pharmacological model. Pharmacological concentrations of human renin and/or prorenin were infused to facilitate the detection of Ang formation from Aogen. In our study, we focused only on acute effects. Prorenin was not activated to active renin and did not affect MAP. Furthermore, renin uptake and vascular Ang formation were also not affected by prorenin.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Animals
Male and female heterozygous Sprague-Dawley rats harboring the complete human genomic Aogen gene, TGR(hAOGEN) 1623, and weighing 300 to 400 g were used for all experiments. The transgenic line was developed as outlined elsewhere.22 The rats were kept in rooms at 24±2°C and were fed a standard rat diet (No. C-1000, Altromin) containing 0.2% sodium by weight and were allowed free access to tap water. All procedures were done according to guidelines from the American Physiological Society and were approved by local authorities (AZ IV A4/5-G 0399/92 and AZ IV A4/5-G 022/94).
Hindquarter Perfusion
Preparation and perfusion were performed with rats under
thiopental anesthesia (75 mg/kg IP) as previously
described.6 Briefly, rats underwent median laparotomy.
After evisceration, the abdominal aorta and the inferior
vena cava were cannulated, and the perfusion was started immediately.
Two hindquarters were perfused in parallel in a nonrecirculating system
with a modified Tyrode's solution containing 2 g/L glucose and 20 g/L
of the artificial colloid Ficoll 70 (Pharmacia). The perfusate
was gassed with a mixture of
O2/CO2 (95%/5%), adjusted
to pH 7.4, and maintained at 37°C. The hindquarter perfusion was
performed at a constant flow rate of 10 mL/min with a peristaltic pump
(Abimed Gilson), and the perfusion pressure was monitored by a pressure
transducer connected to an on-line computer system (TSE). Protocols
were started after 30 minutes of equilibration perfusion. All
experimental substances, including renin, were infused into the
perfusion system at a rate of 100 µL/min by means of a syringe pump
(HT Infusors).
Experimental Protocols
Hindlimb Perfusion
After an initial 30-minute period of baseline perfusion,
perfusate for measurement of peptides was collected after 3, 6,
9, 12, 15, 20, 25, 30, 35, 40, and 45 minutes. All perfusate
samples were collected over a period of 9 seconds in the presence of a
cocktail containing 26 mmol/L phenanthroline (Sigma Chemie),
125 mmol/L EDTA (Sigma Chemie), and a human specific renin
inhibitor (remikiren, Hoffmann–La Roche)
(10-5 mol/L) to prevent any Ang formation
outside the hindlimb. Remikiren completely blocks renin activity during
sample collection and handling. Enzyme-kinetic renin measurements were
performed without remikiren. Purified human recombinant renin and
prorenin produced in a Chinese hamster ovary expression
system23 were infused for 15 and 20 minutes, respectively.
Human recombinant prorenin always exhibited a small active renin
contamination; therefore, we used the term "total renin." The
samples were immediately frozen on dry ice and stored at -80°C until
assayed. One sample was obtained after the washout period of each
experiment to exclude contamination of the perfusion system with human
renin and Ang peptides.
Vascular Ang I Release
This protocol was performed to investigate whether prorenin can
be activated to active renin and generate Ang I from Aogen in
the hindlimb preparation. Human recombinant prorenin (15 ng/mL) was
infused for 15 minutes, and the perfusate was collected over a
period of 9 seconds as described above in 6 hindlimb preparations.
Renin infusions were stopped after 15 minutes; collections were
continued to 45 minutes. The perfusate contained
10-5 mol/L captopril to inhibit any conversion
of Ang I to Ang II. We also investigated the effect of prorenin on
renin-induced vascular Ang I formation. In 4 separate experiments,
human renin (10 ng/mL) was infused for 15 minutes. A 20-minute infusion
of prorenin was started 2 minutes before renin infusion, and the
perfusate was collected as described above.
Effects of Renin and/or Prorenin on MAP and Plasma Ang II
Levels
The protocol was performed in anesthetized rats
transgenic for human Aogen (pentobarbital 60 mg/kg IP) to determine the
effects on MAP and plasma Ang II levels. Either saline, renin (9 ng),
or prorenin (9, 20, and 154 ng total renin) was injected in 5 to 12
experiments at each dose into the vena jugularis. MAP was recorded
with a pressure transducer connected to an implanted catheter (in the
arteria femoralis) and on-line computer system (TSE). In 3 to 5
experiments, 9 and 154 ng total renin were injected, followed by a 9-ng
renin injection 25 minutes after the first bolus. Blood (600 mL) was
withdrawn via the arteria femoralis 15 minutes after each injection in
the presence of a cocktail containing 26 mmol/L phenanthroline
(Sigma Chemie) and 125 mmol/L EDTA (Sigma Chemie) and a human
specific renin inhibitor (remikiren, Hoffmann–La Roche,
10-5 mol/L) to prevent any ex vivo Ang
formation. Blood withdrawal did not affect MAP. The volume was replace
by saline. Blood samples were centrifuged, frozen on dry ice,
and stored at -80°C until analyzed.
Enzyme-Kinetic Determinations and RIA
Immunoreactive Ang I and Ang II concentrations were determined
by direct radioimmunoassay (RIA). Details of the RIA are described
elsewhere.6 There was no interference of remikiren or
captopril in these immunoassays. The limit of detection was 2 fmol/mL
for Ang II and 0.1 ng Ang I · mL-1
· h-1 for human renin.
Human renin concentration was determined by a similar enzyme-kinetic assay.6 Plasma from 48-hour, bilaterally nephrectomized TGR(hAOGEN) 1623 rats was used as a source of excess renin substrate. All samples were incubated together with nephrectomized transgenic rat plasma at pH 5.7 and 37°C for 1 or 2 hours. Rat Aogen was not cleaved during incubation because of the absence of any detectable rat renin in the perfusate. Ang I generated during the enzyme-kinetic assays was measured by direct RIA, and human renin concentration was expressed as pmol Ang I · mL-1 · h-1.
Activation of Inactive Renin (Prorenin) by Trypsin
Perfusate (25 µL) was incubated at 4°C for 10
minutes with 25 µL trypsin (40 µg/mL) in 0.1 mol/L sodium
phosphate, pH 7.5, containing 0.1% BSA. The reaction was stopped by
the addition of 100 µL of soybean trypsin inhibitor (1
mg/mL) in 0.2 mol/L sodium phosphate/citrate buffer, pH 5.7, containing
0.1% BSA and 2% EDTA.
Determination of Prorenin
From each sample, renin concentration (total renin) after its
activation by trypsin and the plasma renin concentration were
determined. Direct renin measurements were performed with an IRMA
Pasteur kit (Sanofi Pasteur) according to the manufacturer's
instructions. The amount of human prorenin was calculated by
subtracting the amount of human renin from each sample of the total
renin amount after activation of inactive renin. The amounts of human
prorenin and human renin of the infused or injected stock solutions
were determined before the experiments.
Statistical Analysis
Data are expressed as mean±SEM. Repeated-measures ANOVA was
used to study the influence of renin and/or prorenin infusion and time
of perfusion on Ang I release and changes in MAP, followed by unpaired
Student's t test as a post hoc test. Statistical
significance between protocols with coinfusion of
inhibitors was estimated by 1-way ANOVA and
Scheffé's test. A numerical value of P<0.05 was
accepted as significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The perfusion pressure of the isolated rat hindquarters ranged from 18 to 22 mm Hg. No Ang I or II could be measured in samples taken before the infusion of human renin and/or prorenin. Addition of renin (10 ng/mL) to the perfusate led to release of readily detectable amounts of Ang I from the perfused rat hindquarters (Figure 1
). These experiments were performed in
the presence of captopril; no change of perfusion pressure was
detected. Renin caused no Ang I formation if infused into nontransgenic
rat hindquarters or into perfusion channels without hindquarter
preparation.
|
The time course of renin and Ang I concentration after cessation of
renin infusion (Figure 1
) provided evidence for uptake of renin
to vascular tissue. Renin in venous perfusate decreased sharply
to barely detectable levels within 5 to 10 minutes, whereas Ang I
release remained elevated and constant (Figure 1). The enzyme
was clearly still active at the vascular wall despite its absence from
the perfusate. The infusion of 15 ng/mL of total renin (14
ng/mL prorenin; 1 ng/mL renin) caused no detectable Ang I release from
the preparation. No activation of prorenin to active renin was seen in
these experiments. We also tested whether human prorenin may act as an
endogenous competitor for renin uptake in the tissue
(Figure 2). Coinfusion of human renin
with a 15-fold excess of total renin (144 ng/mL prorenin) did not
affect local vascular Ang I release (117±10 versus 123±12 fmol/mL 30
minutes after cessation of the infusion).
|
We then investigated the effects of human prorenin and/or human renin
on MAP. Saline bolus injection in anesthetized male rats
transgenic for human Aogen did not affect MAP (MAP, -1±2
mm Hg). Total renin injections of 9, 20, and 154 ng did not increase
MAP (1±2, 4±3, and 10±5 mm Hg, respectively). Conversely, 9 ng
of active renin caused a significant increase of 37±3 mm Hg
(Figure 3A). To investigate whether
prorenin could influence the renin-induced pressure response, we first
injected either 9 or 154 ng total renin, which was followed by a 9-ng
renin bolus 15 minutes later. Both protocols showed a similar increase
in MAP (Figure 3A), which was not different from renin alone
(46±4, 41±4, and 37±3 mm Hg, respectively). Human renin and/or
prorenin injections in female TGR(hAOGEN)1623 rats show a similar
picture (data not shown). Plasma Ang II levels are shown in Figure 3B. Total renin injections (9, 20, and 154 ng) showed no
differences in plasma Ang II compared with saline (55±2, 40±21, and
61±5 fmol/mL versus 40±5 fmol/mL, respectively). Ang II levels after
renin injection alone were significantly increased compared with saline
or total renin injections but were not different from plasma Ang II
levels with total renin plus renin injections (Figure 3B). The
effects of time course on MAP after subsequent bolus injections
of either saline plus 9 ng active renin or 154 ng total renin plus 9 ng
active renin are shown in Figure 4. Both
protocols showed a similar pattern, indicating that prorenin was not
activated and that it did not affect renin-induced
effects on MAP.
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The physiological role of prorenin is unknown; however, the possibility that prorenin inhibits the effects of renin locally has been raised.9 We tested the hypothesis that prorenin may be an endogenous competitor for renin uptake in the tissue. We also investigated whether prorenin can be activated to active renin and affect MAP. Therefore, we used transgenic rats with a high overexpression of human Aogen22 to study the formation of Ang peptides at the level of the vascular wall and in the circulation. We infused human recombinant renin and prorenin generated by Chinese hamster ovary cells,23 which show similar properties with respect to molecular weight, kinetic activity, activation and immunological characteristics, and binding to a Cibacron blue affinity column compared with human plasma and renal inactive renin.24 Our study focused on acute effects. Prorenin was not activated to active renin at the site of the tissues or in the circulation. MAP was neither increased nor decreased after prorenin injections. Furthermore, renin-induced Ang formation was also not affected by prorenin. We cannot state whether renin was taken up specifically because of its physicochemical properties or because of nonspecific sequestration in the extravascular space. We conclude that prorenin does not act as an endogenous antagonist for the long-lasting effects of renin in the vascular wall.
Evidence for renin binding to several receptors or proteins has been reported by several investigators,7 8 10 25 26 who suggested that renin is actively taken up by tissues or into the cell. The extent of binding as well as the consequences of the binding differ markedly between organs. Sealey et al9 described a prorenin-binding protein, with the highest binding capacity of membranes in the kidney, liver, and testis but low binding capacity in heart and aorta and almost none in skeletal muscle. Therefore, the possibility that the prorenin-binding protein is a candidate for interaction in our model is not very likely. Nevertheless, the injection of prorenin and/or renin into intact animals in our in vivo experiments addressed the possible interaction with the prorenin-binding protein. However, we found no evidence for an increase or decrease in MAP after prorenin injection in intact rats. This finding is in line with the unaltered plasma Ang II levels. No changes in MAP or plasma Ang II were observed after subsequent injections of prorenin and renin. This observation speaks against the notion that prorenin may regulate MAP and/or plasma Ang II levels in our short-term experiments.
Campbell and Valentijn8 reported on a different renin-binding protein in vascular tissue. They described the highest binding capacity in mesenteric arteries. Thus, we speculated that renin and/or prorenin might bind to this protein in our isolated perfused resistance vessel bed. Our present data clearly demonstrate an uptake of human renin into vascular tissue and a local action, because the effects of renin were still present after cessation of renin infusion, when renin activity in the perfusate was almost undetectable. The infusion of prorenin did not cause any vascular Ang formation. However, vascular Ang formation was not different after competition of prorenin with renin for a putative receptor, compared with renin-induced Ang formation. Therefore, we are tempted to speculate that renin and prorenin do not bind to the same receptor. Alternatively, renin uptake could be mediated by nonspecific sequestration in the extravascular space. However, we believe that the long-lasting renin-induced local Ang formation is of (patho)physiological importance, irrespective of the mechanism of uptake. We cannot completely exclude the possibility that human renin binding and/or human prorenin binding to rat binding proteins could be hampered by species specificity. However, we and others have obtained similar results for local Ang formation with different renin sources in the rat model.6 27 28 29
Recently, Hu et al30 showed identical hemodynamic and hormonal responses to 14-day infusions of renin or Ang II in conscious rats. They concluded that tissue-bound renin does not play a unique role in promoting cardiovascular, renal, hormonal, or drinking responses. However, several investigators, including ourselves,31 32 have shown that Ang II–induced end-organ damage in the kidney and heart is not only influenced by systemic blood pressure and circulating Ang II levels .
Activation of prorenin was reported by several groups. Hsueh et al34 identified a 25-kDa enzyme in the kidney, which was able to activate human recombinant prorenin. Trypsin, plasmin, pepsin, kallikrein, and other proteases can also activate prorenin.11 33 34 However, some of these enzymes are unlikely candidates to process active renin, because, for example, trypsin and pepsin also degrade renin. Recently, van Kesteren et al10 reported that human renin and human prorenin were taken up into neonatal rat cardiac myocytes and fibroblasts by the mannose-6 phosphate receptor. Prorenin was activated in the cell within a few minutes. Nevertheless, it remains unclear whether intracellularly activated prorenin only contributes to intracellular communication or is secreted back into the circulation or whether this pathway is merely an extrahepatic mechanism of degradation. Experiments in primates showed that the liver and kidney may take up circulating prorenin and convert prorenin to active renin without secreting renin back into the circulation.34 The unchanged release of Ang in the perfusate and unaltered plasma Ang II levels we observed could be explained by such mechanisms.
Experimental and epidemiological data have demonstrated an important role for the RAS in the pathogenesis of hypertension and end-organ damage. However, the role of prorenin in the pathogenesis of hypertension and end-organ damage remains uncertain,12 35 although elevated plasma prorenin concentrations have been implicated as a cause of microangiopathy in diabetic patients.36 A newly developed transgenic rat model developed by Veniant et al37 that overexpresses rat prorenin in the liver exhibited a 400-fold increase in plasma prorenin. The transgenic model showed cardiac hypertrophy and severe renal lesions in the absence of blood pressure. Thus, the model demonstrated that long-term exposure to elevated plasma prorenin is vasculotoxic. One possible explanation is that during the inflammatory process, neutrophils produce abundant enzymes that possibly activate prorenin and thereby enhance local Ang II levels.38 Our results are limited by the fact that we focused on only short-term effects. Nevertheless, the very rapid activation of prorenin in vitro would predict detectable short-term effects.
In summary, our data showed that human recombinant prorenin was not activated to active renin at the site of the vascular tissue or in the circulation. In the isolated perfused hindquarter, human renin can be taken up from the circulation and remains active much longer than its presence in the circulation would explain. The renin-induced vascular Ang I formation was not influenced by prorenin, indicating that prorenin is not acting as an endogenous competitor for renin uptake to the vascular wall. In vivo, MAP was neither increased nor decreased after prorenin injections. Competition of prorenin and renin did not affect MAP and plasma Ang II compared with renin injection alone. Therefore, we conclude that prorenin does not act as an endogenous antagonist of renin for its uptake in the vascular wall and does not influence renin-induced effects on blood pressure in short-term experiments. Further studies are necessary to determine the importance of intracellular activation of prorenin and its long-term effects on end-organ damage.
|
Acknowledgments |
|---|
This study was supported by a grant in aid from the Bundesministerium für Bildung und Forschung, Bonn, Germany, and Hoffmann–La Roche, Basel, Switzerland. We gratefully acknowledge the expert technical assistance of Irene Strauss, Gabriele Born, and Josiane Rein.
Received September 17, 1998; first decision October 26, 1998; accepted November 6, 1998.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Campbell DJ. Circulating and tissue angiotensin systems. J Clin Invest. 1987;79:1–6.
2.
Admiraal PJ, Derkx FH, Danser AH, Pieterman H,
Schalekamp MA. Metabolism and production of
angiotensin I in different vascular beds in subjects with
hypertension. Hypertension. 1990;15:44–55.
3.
Danser AH, Koning MM, Admiraal PJ, Sassen LM, Derkx
FH, Verdouw PD, Schalekamp MA. Production of
angiotensins I and II at tissue sites in intact pigs.
Am J Physiol. 1992;263:H429–H437.
4.
Danser AH, van Kats JP, Admiraal PJ, Derkx FH, Lamers
JM, Verdouw PD, Saxena PR, Schalekamp MA. Cardiac renin and
angiotensins: uptake from plasma versus in situ synthesis.
Hypertension. 1994;24:37–48.
5.
Kato H, Iwai N, Inui H, Kimoto K, Uchiyama Y, Inagami
T. Regulation of vascular angiotensin release.
Hypertension. 1993;21:446–454.
6.
Muller DN, Hilgers KF, Bohlender J, Lippoldt A, Wagner
J, Fischli W, Ganten D, Mann JF, Luft FC. Effects of human renin in the
vasculature of rats transgenic for human angiotensinogen.
Hypertension. 1995;26:272–278.
7. Nguyen G, Decarue F, Berrou J, Rondeau E, Sraer J. Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen. Kidney Int. 1996;50:1897–1903.[Medline] [Order article via Infotrieve]
8. Campbell DJ, Valentijn AJ. Identification of vascular renin-binding proteins by chemical cross-linking: inhibition of binding of renin by renin inhibitors. J Hypertens. 1994;12:879–890.[Medline] [Order article via Infotrieve]
9. Sealey JE, Catanzaro DF, Lavin TN, Gahnem F, Pitarresi T, Hu LF, Laragh JH. Specific prorenin/renin binding (ProBP): identification and characterization of a novel membrane site. Am J Hypertens. 1996;9:491–502.[Medline] [Order article via Infotrieve]
10.
van Kesteren CAM, Danser AHJ, Derkx FHM, Dekkers DHW,
Lamers JMJ, Saxena PR, Schalekamp MA. Mannose 6-phosphate
receptor–mediated internalization and activation of prorenin by
cardiac cells. Hypertension. 1997;30:1389–1396.
11.
Sealey JE, Atlas SA, Laragh JH. Prorenin and other
large molecular weight forms of renin. Endocrinol Rev. 1980;1:365–391.
12. Sealey JE, Rubattu S. Prorenin and renin as separate mediators of tissue and circulating systems. Am J Hypertens. 1989;2:358–366.[Medline] [Order article via Infotrieve]
13. Reudelhuber TL, Ramla D, Chiu L, Mercure C, Seidah NG. Proteolytic processing of human prorenin in renal and non-renal tissues. Kidney Int. 1994;46:1522–1524.[Medline] [Order article via Infotrieve]
14. Shaw KJ, Do YS, Kjos S, Anderson PW, Shinagawa T, Dubeau L, Hsueh WA. Human decidua is a major source of renin. J Clin Invest. 1989;83:2085–2092.
15. Sealey JE, White RP, Laragh JH, Rubin AL. Plasma prorenin and renin in anephric patients. Circ Res. 1977;41:17–21.[Medline] [Order article via Infotrieve]
16.
Lenz T, Sealey JE, Maack T, James GD, Heinrikson RL,
Marion D, Laragh JH. Half-life, hemodynamic, renal, and
hormonal effects of prorenin in cynomolgus monkeys. Am J
Physiol. 1991;260:R804–R810.
17. Sealey JE, Moon C, Laragh JH, Alderman M. Plasma prorenin: cryoactivation and relationship to renin substrate in normal subjects. Am J Med. 1976;61:731–738.[Medline] [Order article via Infotrieve]
18. Hsueh WA, Do YS, Wang PH. Observations on the renal processing and sorting of prorenin. Can J Physiol Pharmacol. 1991;69:1327–1330.[Medline] [Order article via Infotrieve]
19. Derkx FH, de Bruin RJ, van Gool JM, Rosmalen FM, van Hoek MJ, Beerendonk CC, Schalekamp MA. A novel assay of plasma prorenin using a renin inhibitor. J Hypertens. 1993;11(suppl):S240–S241.
20. Derkx FH, Schalekamp MP, Schalekamp MA. Role of intrinsic inhibitors in acid-activation of inactive plasma renin (prorenin). Clin Exp Hypertens. 1982;4:2123–2131.
21. Leckie EJ. The reversible activation of inactive renin in human plasma: role of acid and of plasma kallikrein and plasmin. Clin Exp Hypertens. 1982;4:2133–2147.
22.
Ganten D, Wagner J, Zeh K, Bader M, Michel JB, Paul M,
Zimmermann F, Ruf P, Hilgenfeldt U, Ganten U, Kaling M, Bachmann S,
Fukamizu A, Mullins J, Murakami K. Species specificity of renin
kinetics in transgenic rats harboring the human renin and
angiotensinogen genes. Proc Natl Acad Sci
U S A. 1992;89:7806–7810.
23. Mathews S, Dobeli H, Pruschy M, Bosser R, D'Arcy A, Oefner C, Zulauf M, Gentz R, Breu V, Matile H, Schlaeger J, Fischli W. Recombinant human renin produced in different expression systems. Protein Expr Purif. 1996;7:81–91.[Medline] [Order article via Infotrieve]
24. Hsueh WA, Do YS, Shinagawa T, Tam H, Ponte PA, Baxter JD, Shine J, Fritz LC. Biochemical similarity of expressed human prorenin and native inactive renin. Hypertension. 1986;8:78–83.
25.
Loudon M, Bing RF, Thurston H, Swales JD.
Arterial wall uptake of renal renin and blood pressure
control. Hypertension. 1983;5:629–634.
26.
Thurston H, Swales JD, Bing RF, Hurst BC, Marks ES.
Vascular renin-like activity and blood pressure maintenance in
the rat: studies of the effect of changes in sodium balance,
hypertension and nephrectomy. Hypertension. 1979;1:643–649.
27.
De Lannoy LM, Danser AHJ, van Kats JP, Schoemaker
RG, Saxena PR, Schalekamp MADH. Renin-angiotensin system
components in the interstitial fluid of the isolated
perfused rat heart. Hypertension. 1997;29:1240–1251.
28.
de Lannoy LM, Danser AH, Bouhuizen AM, Saxena PR,
Schalekamp MA. Localization and production of
angiotensin II in the isolated perfused rat heart.
Hypertension. 1998;31:1111–1117.
29.
Hilgers KF, Bingener E, Stumpf C, Muller DN, Schmieder
RE, Veelken R. Angiotensinases restrict locally generated
angiotensin II to the blood. Hypertension. 1998;31:368–372.
30. Hu L, Catanzaro DF, Pitarresi TM, Laragh JH, Sealey JE. Identical hemodynamic and hormonal responses to 14-day infusions of renin or angiotensin II in conscious rats. J Hypertens. 1998;16:1285–1298.[Medline] [Order article via Infotrieve]
31. Luft FC, Mervaala E, Muller DN, Gross V, Schmidt F, Park J-K, Schmitz C, Lippoldt A, Breu V, Dechend R, Dragun D, Schneider W, Ganten D, Haller H. Hypertension-induced end-organ damage: a new transgenic approach to an old problem. Hypertension. 1999;33(part II):212–218.
32.
Mazzolai L, Nussberger J, Aubert JF, Brunner DB,
Gabbiani G, Brunner HR, Pedrazzini T. Blood pressure–independent
cardiac hypertrophy induced by locally activated
renin-angiotensin system. Hypertension. 1998;31:1324–1330.
33.
Inagami T, Okamoto H, Ohtsuki K, Shimamoto K, Chao J,
Margolius HS. Human plasma inactive renin: purification and activation
by proteases. J Clin Endocrinol Metab. 1982;55:619–627.
34.
Hsueh WA, Baxter JD. Human prorenin.
Hypertension. 1991;17:469–477.
35. Nielsen AH, Poulsen K. Is prorenin of physiological and clinical significance? J Hypertens. 1988;6:949–958.[Medline] [Order article via Infotrieve]
36. Wilson DM, Luetscher JA. Plasma prorenin activity and complications in children with insulin-dependent diabetes mellitus. N Engl J Med. 1990;323:1101–1106.[Abstract]
37. Veniant M, Menard J, Bruneval P, Morley S, Gonzales MF, Mullins J. Vascular damage without hypertension in transgenic rats ex-pressing prorenin exclusively in the liver. J Clin Invest. 1996;98:1966–1970.[Medline] [Order article via Infotrieve]
38.
Dzau VJ, Gonzalez D, Kaempfer C, Dubin D, Wintroub BU.
Human neutrophils release serine proteases capable of activating
prorenin. Circ Res. 1987;60:595–601.
This article has been cited by other articles:
 |
|
 |
|
  J. Zhang, N. A. Noble, W. A. Border, R. T. Owens, and Y. Huang Receptor-dependent prorenin activation and induction of PAI-1 expression in vascular smooth muscle cells Am J Physiol Endocrinol Metab, October 1, 2008; 295(4): E810 - E819. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Campbell Critical Review of Prorenin and (Pro)renin Receptor Research Hypertension, May 1, 2008; 51(5): 1259 - 1264. [Full Text] [PDF]
|
|
|
|
 |
|
 D. N Muller and F. C Luft Effects of human prorenin in rats transgenic for human angiotensinogen revisited Journal of Renin-Angiotensin-Aldosterone System, March 1, 2008; 9(1_suppl): S4 - S5. [PDF]
|
|
|
|
|
|
A.H. J. Danser and J. Deinum Renin, Prorenin and the Putative (Pro)renin Receptor Hypertension, November 1, 2005; 46(5): 1069 - 1076. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Peters, R. Farrenkopf, S. Clausmeyer, J. Zimmer, S. Kantachuvesiri, M. G.F. Sharp, and J. J. Mullins Functional Significance of Prorenin Internalization in the Rat Heart Circ. Res., May 31, 2002; 90(10): 1135 - 1141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. F. Hilgers, R. Veelken, D. N. Muller, H. Kohler, A. Hartner, S. R. Botkin, C. Stumpf, R. E. Schmieder, and R. A. Gomez Renin Uptake by the Endothelium Mediates Vascular Angiotensin Formation Hypertension, August 1, 2001; 38(2): 243 - 248. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. E. D. van den Eijnden, J. J. Saris, R. J. A. de Bruin, E. de Wit, W. Sluiter, T. L. Reudelhuber, M. A. D. H. Schalekamp, F. H. M. Derkx, and A. H. J. Danser Prorenin Accumulation and Activation in Human Endothelial Cells : Importance of Mannose 6-Phosphate Receptors Arterioscler Thromb Vasc Biol, June 1, 2001; 21(6): 911 - 916. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||